New Type 2 Diabetes Drug AIMS to Reduce Risk of Diminished Kidney Function and Cardiovascular Complications

Am J Nurs. 2021 Nov 1;121(11):22-23. doi: 10.1097/01.NAJ.0000798996.63395.dc.ABSTRACTFinerenone (Kerendia) has been approved to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.PMID:34673691 | DOI:10.1097/01.NAJ.0000798996.63395.dc

Source: The American Journal of Nursing - October 21, 2021 Category: Nursing Authors: Diane S Aschenbrenner Source Type: research